ELIXIRGEN, LLC
ZSCAN4 protein biologic to extend telomeres and treat dyskeratosis congenita
- Sector
- Biotech
- Headquarters
- BALTIMORE, MD
- Founded
- 2012
- Latest Form D
- $300K, Apr 2012
- Total capital
- $448K
- Federal grants
- $148K
- 1 award · 2016
- Rank in peer group#12 of 1449
- Private capital raised
- $300K
- 1 Form D · last Apr 2012
- 174 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 4 pending · first 2019
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Development of a novel biologic medical product for Dyskeratosis Congenita$148K
- Private capital raisedForm D · SEC · 1st filing$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Federal grants#12 · top 1%
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Minoru Shil Hong KoDirectorNamed in SEC Form D filings
- Naomi Takahashi KoExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 5- GrantedMethods Of Using ZSCAN4 For Rejuvenating Human CellsUSPTOUS 10,335,456
- PendingCompositions And Methods For Differentiation Of Human Pluripotent Stem Cells Into Desired Cell TypesUSPTOApplication 62523324
- PendingCompositions And Methods For Differentiation Of Human Pluripotent Stem Cells Into Desired Cell TypesUSPTOApplication 62465188
Show all 5 patent records
- Methods Of Using ZSCAN4 For Rejuvenating Human CellsJul 2, 2019 · US 10,335,456Granted
- Compositions And Methods For Differentiation Of Human Pluripotent Stem Cells Into Desired Cell TypesApplication 62523324Pending
- Compositions And Methods For Differentiation Of Human Pluripotent Stem Cells Into Desired Cell TypesApplication 62465188Pending
- Methods Of Using ZSCAN4 For Rejuvenating Human CellsApplication PCTUS2014029537Pending
- Methods Of Using ZSCAN4 For Rejuvinating Human CellsApplication 61800668Pending
Related companies, and why
- Accipiter Biosciences Inc.Similar federal contract value in Biotech · null in contracts
- LAVO LIFE SCIENCES INCSimilar federal contract value in Biotech · null in contracts
- Violet TherapeuticsSimilar federal contract value in Biotech · null in contracts
- TERNALYS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Gateway Bio, Inc.Similar federal contract value in Biotech · null in contracts
- NEURONASAL INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .